Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
carbidopa
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N04BA02
|
| gptkbp:CASNumber |
28860-95-9
|
| gptkbp:category |
antiparkinsonian agent
|
| gptkbp:combines |
gptkb:levodopa
|
| gptkbp:developedBy |
gptkb:Merck
|
| gptkbp:discoveredIn |
1960s
|
| gptkbp:hasMolecularFormula |
C10H14N2O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
MK-906
|
| gptkbp:mechanismOfAction |
aromatic L-amino acid decarboxylase inhibitor
|
| gptkbp:prevention |
peripheral conversion of levodopa to dopamine
|
| gptkbp:reduces |
side effects of levodopa
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:orthostatic_hypotension
nausea dizziness |
| gptkbp:usedFor |
gptkb:Parkinson's_disease
|
| gptkbp:bfsParent |
gptkb:finasteride
|
| gptkbp:bfsLayer |
6
|